Posted by Michael Wonder on 25 Jul 2021
COVID-19 demand leads to Australian shortages of rheumatoid arthritis drug
25 July 2021 - Australia is facing shortages of a rheumatoid arthritis drug that has been used to treat COVID-19 overseas, with supply expected to be constrained into next year.
Roche has warned the TGA that the pandemic has restricted supply of a variety of medicines under the brand name Actemra.
